Abstract: Low molecular weight heparin(LMWH) can reduce the risk of bleeding caused by heparin while achieving effective anticoagulation, which has certain clinical application value. The application of low molecular heparin in obstetric diseases has draw extensive attention. It has been used in the prophylaxis and treatment of pre-eclampsia(PE) and fetal growth restriction(FGR) caused by thrombophilia besides the prevention of deep venous thrombosis(DVT). The use of LMWH may be considered after assessing the risk factors of DVT in gestational period and puerperium. More researches have found the improvement of outcome of LMWH in the non-thrombophilia pregnancy. It can reduce the risk of preeclampsia and FGR in high-risk groups (pregnancy women with history of placental abruption and early-onset PE), and improve their pregnancy outcome, such as prolonging the gestational age, improving newborn survival rate and birth weight. We reviewed recent studies about the application of LMWH in DVT, PE and FGR.

Key words: Heparin, low-molecular-weight, Venous thrombosis, Pre-eclampsia, Fetal growth retardation